Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol for spasticity in multiple sclerosis patients with gait disorders
IRCT20220815055709N1Phase 3Completed
- Sponsor
- Khosro Medisa Teb
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of cannabidiol in multiple sclerosis (MS) and Muscle spasm, sponsored by Khosro Medisa Teb. Primary endpoint: Change in spasticity severity. Started Jan 2023; status: completed.
02
Drugs
cannabidiol
03
Conditions
multiple sclerosis (MS)Muscle spasm
Beyond the preview
Go deeper on IRCT20220815055709N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220815055709N1.